Today on #WorldCancerDay we're proud to support our 13K members worldwide as they work on the fundamental research that leads to treatment breakthroughs. #UnitedbyUnique

What's the Land of Tomorrow of #IO in #NSCLC? At #ESMOImmune2024 I had the honor to discuss the data on 🔴 PDC*lung01 vaccine + Pembro in 1L PD-L1 high 🔴 Inupadenant +carbo/pem after IO failure 🔴 Effectiveness & immunophenotype in orphan genomic alterations @oncoalert.bsky.social #lcsm

Exciting data at #ESMOImmumo2024 showed by George Coukos on adoptive immune cell therapies: 🔵 Nb of reactive antitumor TILs that are injected correlate with response 🔵 How to improve #TIL treatments in pts with #melanoma @oncoalert.bsky.social

How to counteract the immunosuppressive action of #adenosine in #TNBC? @laubdh.bsky.social explains her journey from bench to bedside with the SYNERGY and NeoCheckRay trials & the intense ongoing TR to understand who're the pts who benefit from anti-CD73 🔬👏💪 @oncoalert.bsky.social #ESMOImmuno2024

When @marianabrandao0.bsky.social makes us travel from Geneva #ESMOImmuno24 to Tomorrowland and the Smurf Village throught a brillant discussion of 3 mini orals about treatment strategies for NSCLC patients. Thank you!

Excellent discussion by @marianabrandao0.bsky.social on treatment of patients with #NSCLC #ESMOImmuno24 Insightful perspectives on recent advances!

🧑‍⚕️ Calling #YoungOncologists - Have an idea for a trial or study? The annual #MCCRWorkshop now open for applications! 🗓️ Deadline 31 Jan 2025 @mcrcnews.bsky.social 🔗 ow.ly/2KEB50UohRW

Initiation visit this morning at Institut Jules Bordet of the EmpowHER 303 phase 3 study of anti-HER2 bispecific antibody zanidatamab in combination with chemo vs trastuzumab and chemo in HER2+ MBC. clinicaltrials.gov/study/NCT064... #bcsm

💥40 years ago today a 33 y/o dying of #metastatic #melanoma got #LAK & #IL-2 & all #cancer went away! Dr. S.A. #Rosenberg (SAR) had the #immune system #cure a patient/I was in SAR’s lab 85-90/incredible era & energy/Great story in @usatoday.com apple.news/AIcm-M7cDQ-O... @sitcancer.bsky.social

Congratulations @mattiarediti.bsky.social & Christos Sotiriou for this extraordinary work on HER2+ breast cancer!! 💪👏👏

Impact of cycle 1 irAEs on ICI outcomes: - 683pts from SWOG DART trial - g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001 - g3+ irAEs = ⬇️OS HR  1.41 p= .025 - g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002 Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social academic.oup.com/jnci/advance...

⭐️Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Nice work spearheaded by @adesaimd.bsky.social mdpi.com/3031120

Impressive talk by Barbara Pistilli on #ADCs at the 18th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice by #BSMO & #JulesBordet 🚨 🔴How ADCs are made? 🔴What mechanisms of resistance? 🔴How to improve efficacy? @oncoalert.bsky.social

🧑‍🔬🏛️👩‍⚕️ Lots of our #CancerImmunology community now here 🦋, including @jimallisonphd.bsky.social 🏅! #AcademicSky #ImmunoSky #OncSky #StarterPack 1 is already full 🙌, so starting a another one. Let's continue growing! - Pack 1️⃣: go.bsky.app/PRdmHCP - Pack 2️⃣: go.bsky.app/93eqJbs

Don't miss the next #ESMO Virtual Journal Club on Wed 4/Dec🔎📃 we'll discuss: #LAURA trial: Osi after CRT in #NSCLC 🫁 #RUBY trial: dostarlimab +carbo/paclitaxel in #endometrialcancer 🚨Don't forget to register! 👇 @oncoalert.bsky.social

18th edition of the Belgian Symposium on the Integration of Molecular Biology - Friday 29/11 and Saturday 30/11/2024 Organized by the Institut Jules Bordet, Belgian Society of Medical Oncology (BSMO) and the Oncodistinct network www.bordet.be/fr/18th-edit...

Institut Jules Bordet (part of the) medical oncology team dinner 🤗 @mignatiadis.bsky.social is already here 🦋 and we are lobbying for others to migrate!